<h2>Charting Our Course: Pfizer's Focus on Innovation and Impact in 2025</h2><p>Just a year ago, speaking at the JPMorgan Healthcare Conference, I shared my dissatisfaction with Pfizer's performance in 2023. I also outlined a clear plan, built on five priorities, designed to turn that situation around. Today, I'm pleased to report a different story: one of decisive execution and significant progress across all those goals. We not only met our targets but exceeded them in many areas.</p><p>In 2024, we made transformative changes. The integration of Seagen doubled our oncology R&D capabilities, establishing Pfizer as a leading force in the field. We revitalized our commercial engine, achieving market share gains beyond expectations. Our commitment to efficiency led to a $4 billion reduction in our cost base, with an additional $1.5 billion in margin improvements announced. We also restructured our R&D organization and refreshed our Board, while returning substantial capital to sh...
<h2>Charting Our Course: Pfizer's Focus on Innovation and Impact in 2025</h2><p>Just a year ago, speaking at the JPMorgan Healthcare Conference, I shared my dissatisfaction with Pfizer's performance in 2023. I also outlined a clear plan, built on five priorities, designed to turn that situation around. Today, I'm pleased to report a different story: one of decisive execution and significant progress across all those goals. We not only met our targets but exceeded them in many areas.</p><p>In 2024, we made transformative changes. The integration of Seagen doubled our oncology R&D capabilities, establishing Pfizer as a leading force in the field. We revitalized our commercial engine, achieving market share gains beyond expectations. Our commitment to efficiency led to a $4 billion reduction in our cost base, with an additional $1.5 billion in margin improvements announced. We also restructured our R&D organization and refreshed our Board, while returning substantial capital to shareholders through dividends and debt reduction. This comprehensive effort made 2024 a year of strong execution.</p><p>As we look to 2025, our strategic priorities build on this momentum, with a distinct shift in emphasis. Advancing our pipeline and improving R&D productivity and efficiency now stand as our number one priority. This focus is central to our mission of bringing breakthrough medicines to patients faster. We are committed to fostering an environment where scientific discovery can flourish, translating cutting-edge research into tangible health solutions.</p><p>Beyond R&D, we will continue to expand margins through business process simplification and the thoughtful application of technology. In 2024, we already saw AI applications significantly reduce general administrative costs and improve manufacturing yields, and we will build on these efficiencies. We also remain dedicated to commercial excellence across our core therapeutic areas: oncology, vaccines, cardiovascular, migraine, and immuno-inflammation. Finally, our disciplined approach to capital allocation will continue, ensuring we grow our dividend, further reduce debt, and invest strategically back into the business.</p><p>The year 2025 will be another year of execution, centered on creating shareholder value with a strong emphasis on R&D, margin expansion, sustained commercial success, and a shareholder-friendly capital allocation strategy. We are confident in our direction and our ability to deliver on our commitments, driving innovation that makes a meaningful difference for patients worldwide.</p>